Please login to the form below

neurogenics

This page shows the latest neurogenics news and features for those working in and with pharma, biotech and healthcare.

Merck buys cough drug developer Afferent for $1.25bn

Gains access to pipeline with potential for development in ‘neurogenic’ indications. ... These receptors seem to become more common after nerve injury or inflammation, and drugs that block them are thought to have potential in a broad range of

Latest news

Lundbeck agrees $658m deal to buy Chelsea Therapeutics

Chelsea's marketed product - Northera (droxidopa) - was given a green light by the US FDA in February as the first drug specifically approved to treat symptomatic neurogenic orthostatic hypotension (NOH), a
FDA approves Chelsea's rare blood pressure drug

The Food and Drug Administration (FDA) backed Northera capsules (droxidopa) to treat neurogenic orthostatic hypotension (NOH), a chronic drop in blood pressure that is found in patients with Parkinson's disease, ... People with neurogenic orthostatic
FDA panel backs Chelsea's Northera for rare disease

The regulator's Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 16 to 1 in favour of the approval of Northera (droxidopa) to treat symptomatic neurogenic orthostatic hypotension (nOH) in patients ... with an underlying neurogenic disorder,
Positive opinion for Allergan's NDO treatment

A positive opinion is given from the Irish Medicines Board for BOTOX treatment for neurogenic detrusor overactivity (NDO). ... NDO results from neurogenic bladder, due to stable sub-cervical spinal cord injury (SCI) or multiple sclerosis (MS).
Allergan in $600m Botox settlement

The company is currently conducting phase II clinical trials as part of an effort to win marketing approval for neurogenic and idiopathic overactive bladder.

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

Deal Watch June 2016

in development for the treatment of neurogenic conditions, such as chronic cough.
Deal Watch table for June 2014

825. Chelsea Therapeutics/ Lundbeck. Company acquisition. Includes Northera (droxidopa) for neurogenic orthostatic hypotension (approved).
Pharma deals during May 2014

Chelsea has the recently FDA-approved droxidopa, the first and only symptomatic treatment for neurogenic orthostatic hypotension ready for launch later this year.